Literature DB >> 2971275

Propranolol inhalation challenge in relation to histamine response in children with asthma.

J Gerritsen1, G H Koëter, L T Vander Weele, K Knol.   

Abstract

The relation between airway responsiveness to propranolol and histamine was studied in 32 asthmatic children. Propranolol and histamine were given by nebuliser to a maximum dose of 16 mg/ml and 32 mg/ml respectively and the response was measured as the provocative concentration of agonist causing a 20% fall in FEV1 (PC20). A PC20 histamine value of less than 32 mg/ml was obtained in 24 of the 32 children, of whom 15 had a measurable PC20 propranolol (less than 16 mg/ml). In these 24 children the geometric mean PC20 histamine was 4.5 mg/ml and 14.4 mg/ml respectively in those with and without a measurable PC20 propranolol (p = 0.023). There was a linear relationship between histamine and propranolol PC20 values (r = 0.60), and between PC20 histamine and FEV1 % predicted (r = 0.43), but not between PC20 propranolol and FEV1 % predicted (r = 0.38). In an open time course study in 12 children with asthma recovery of FEV1 after inhaled propranolol was incomplete in seven of the children after 90 minutes. When inhaled propranolol was followed by inhaled ipratropium bromide in a further 11 children FEV1 had returned to baseline in all children after 60 minutes. Thus propranolol inhalation can be used in children with asthma to assess the contribution of the beta adrenergic system to the regulation of bronchial smooth muscle tone. The test has several disadvantages in comparison with histamine provocation-long duration, the prolonged action of propranolol, and the fact that only the children with substantial hyperreactivity to histamine react to propranolol.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971275      PMCID: PMC461309          DOI: 10.1136/thx.43.6.451

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  20 in total

Review 1.  Neural control of human airways in health and disease.

Authors:  P J Barnes
Journal:  Am Rev Respir Dis       Date:  1986-12

2.  The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.

Authors:  T L Dunn; M J Gerber; A S Shen; E Fernandez; M D Iseman; R M Cherniack
Journal:  Am Rev Respir Dis       Date:  1986-02

Review 3.  Endogenous catecholamines and asthma.

Authors:  P J Barnes
Journal:  J Allergy Clin Immunol       Date:  1986-06       Impact factor: 10.793

Review 4.  Guidelines for standardization of bronchial challenges with (nonspecific) bronchoconstricting agents.

Authors: 
Journal:  Bull Eur Physiopathol Respir       Date:  1983 Sep-Oct

5.  Role of smooth muscle alpha 1-receptors in nonspecific bronchial responsiveness in asthma.

Authors:  N C Thomson; E E Daniel; F E Hargreave
Journal:  Am Rev Respir Dis       Date:  1982-09

6.  The physical properties of a jet-nebulizer and their relevance for the histamine provocation test.

Authors:  P J Sterk; A Plomp; M J Crobach; J F van de Vate; P H Quanjer
Journal:  Bull Eur Physiopathol Respir       Date:  1983 Jan-Feb

7.  Theoretical Michaelis-Menten elimination model for propranolol.

Authors:  J McAinsh; M A Gay
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jul-Sep       Impact factor: 2.441

Review 8.  The origin of airway hyperresponsiveness.

Authors:  F E Hargreave; J Dolovich; P M O'Byrne; E H Ramsdale; E E Daniel
Journal:  J Allergy Clin Immunol       Date:  1986-11       Impact factor: 10.793

9.  Protective effect of disodium cromoglycate on propranolol challenge.

Authors:  G H Koëter; H Meurs; J G de Monchy; K de Vries
Journal:  Allergy       Date:  1982-11       Impact factor: 13.146

10.  Plasma histamine concentration during propranolol induced bronchoconstriction.

Authors:  P W Ind; P J Barnes; M J Brown; C T Dollery
Journal:  Thorax       Date:  1985-12       Impact factor: 9.139

View more
  1 in total

1.  Bronchoconstriction of the asthmatic airway by inhaled and ingested propranolol.

Authors:  K M Latimer; R E Ruffin
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.